Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma by �꽦吏꾩떎 et al.
? http://www.e-crt.org ?646 Copyright ? 2018 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer Res Treat. 2018;50(3):646-657
pISSN 1598-2998, eISSN 2005-9256
https://doi.org/10.4143/crt.2016.550 
Open Access
Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting 
the Treatment Outcomes in Patients with Hepatocellular Carcinoma
Original Article
Purpose
Early prediction of treatment outcomes represents an essential step towards increased
treatment efficacy and survival in patients with hepatocellular carcinoma (HCC). In this study,
we performed two-dimensional electrophoresis (2-DE) followed by protein profiling to identify
biomarkers predictive of therapeutic outcomes in patients with HCC who received liver-
directed therapy (LDTx) involving local radiotherapy (RT), and studied the underlying mech-
anisms of the identified proteins.  
Materials and Methods
2-DE analysis was conducted by pooling sera from patients with a good or poor prognosis;
serum proteomic profiles of the two groups were compared and analyzed using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry. Identified proteins were
confirmed via enzyme-linked immunosorbent assay. An invasion assay was performed after
overexpression and knockdown of target protein in Huh7 cells. 
Results
Levels of inter-alpha inhibitor H4 (ITIH4), fibrinogen gamma chain, keratin 9/1 complex,
carbonic anhydrase I, and carbonmonoxyhemoglobin S were changed by more than 4-fold
in response to LDTx. In particular, pre-LDTx ITIH4 expression was more than 5-fold higher
in patients with a good prognosis, compared to patients with a poor prognosis. The migration
ability of Huh7 cells was significantly suppressed and enhanced by ITIH4 overexpression
and knockdown, respectively. The tumors of patients with HCC and a good prognosis 
expressed high levels of ITIH4, compared to those of patients with a poor prognosis.   
Conclusion
Taken together, ITIH4 may be a potential therapeutic target that could inhibit cancer metas-
tasis, as well as a prognostic marker for patients with HCC who are receiving LDTx.  
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Introduction
Hepatocellular carcinoma (HCC), which has a high rate of
recurrence and unsatisfactory treatment outcomes, is a criti-
cal global health issue [1,2]. To achieve better oncologic out-
comes, a personalized approach involving the prediction of
therapeutic results, followed by application, has been pro-
posed [3,4] and has led to suggestions of the significance of
biomarkers. The concept of biomarkers is not new in the field
of oncology. These markers, which are defined as biological
molecules found in the blood, other body fluids, or tissues
that indicate a normal or abnormal process, have been exten-
sively studied in various cancers [5,6]. However, investiga-
tive studies of biomarkers for HCC are complex because of
the molecular diversity of HCC itself, as well as associated
conditions related to inflammation and cirrhosis that distin-
guish HCC from other solid malignancies. 
Alpha-fetoprotein (AFP) is a well-known prognostic
marker of HCC, and elevated levels of this protein correlate
with an advanced disease stage and aggressiveness in 
approximately 70% of cases [7]. Nevertheless, AFP does not
yield satisfactory predictions of treatment outcomes, partic-
ularly in cases of AFP-negative HCC.
Active searches for biomarkers have been performed 
recently with the aims of developing and applying these con-
cepts to clinical trials of biomarker-based systemic agents [8].
Although this approach is valuable, biomarkers predictive
of clinical outcomes also seem important for patients with
HCC, particularly those with localized disease but a hetero-
geneous prognosis. The development of high-throughput
serum proteomics techniques has made it possible to identify
serum biomarkers of HCC [9].  
In this study, we investigated possible biomarkers that
could predict the clinical outcomes of patients with HCC,
particularly those with locally advanced disease. Analysis of
sera from patients with HCC was performed to two-dimen-
sional electrophoresis (2-DE) followed by the identification
of possible biomarkers via protein profiling; in addition, the
underlying mechanisms of these biomarkers were eluci-
dated.
Materials and Methods
1. Preparation of serum samples from patients with HCC
This prospectively conducted study conformed to the eth-
ical guidelines of the Declaration of Helsinki; it was 
approved by the Institutional Review Board of Yonsei Sev-
erance Hospital (4-2008-0212). Between September 2008 and
December 2009, a total of 51 patients treated with liver-
directed therapy (LDTx) involving local radiotherapy (RT;
median dose, 45 Gy in 5 weeks) concurrently with hepatic
arterial infusion chemotherapy with 5-fluorouracil, as 
described in a previous report [10], were prospectively 
enrolled in this study. Blood samples were collected before
the start and at the end of the RT schedule. We selected 
patients for inclusion in good (n=10) and poor prognosis
groups (n=10). The 10 patients in the good prognosis group
did not exhibit treatment failure during the follow-up period,
whereas those in the poor prognosis group exhibited early
treatment failure after the completion of RT. Treatment fail-
ures were defined as follows: local failure, recurrence at the
tumor site; regional failure, recurrence in the liver that was
not treated with RT; and distant metastasis, recurrence out-
side the liver.
2. Depletion of majorly abundant proteins using an immu-
noaffinity column
The six most abundant proteins (albumin, transferrin, IgG,
IgA, haptoglobin, and antitrypsin) in serum or plasma were
depleted using a Multiple Affinity Removal Column (MARC;
Agilent, Wilmington, DE). A 4.6-mm50-mm MARC with a
binding capacity for 20 µL of human plasma was used. Chro-
matographic separation of the abundant proteins by MARC
was performed using a mobile phase reagent kit according
to a standard LC protocol provided by the manufacturer.
Briefly, each crude human serum and plasma sample was 
diluted five times with Buffer A containing protease 
inhibitors (COMPLETE, Roche, Basel, Switzerland) and fil-
tered through a 0.22-µm spin filter via centrifugation at
16,000 g and room temperature for 1-2 minutes. The sample
was injected into the MARC, and flow-through fractions
were collected and stored at 20°C until use. To resolve 
depleted plasma proteins on 2-DE gels, flow-through frac-
tions from MARC were pooled and precipitated with a pre-
cooled solution of 10% trichloroacetic acid for 1 hour at
20°C. After washing with ice-cold acetone, pellets were res-
olublized in 2-DE sample buffers.
3. 2-DE and image analysis
2-DE was performed as described previously. First,
aliquots in sample buffer (7 M urea, 2 M thiourea, 4.5%
CHAPS, 100 mM DTE, 40 mM Tris, pH 8.8) were applied to
immobilized pH 3-10 nonlinear gradient strips (Amersham
Biosciences, Uppsala, Sweden). Isoelectric focusing was per-
formed at 80,000 Vh. The second dimension was analyzed on
9%-16% linear gradient polyacrylamide gels (18 cm20 cm
1.5 mm) at a constant 40 mA per gel for approximately 5
hours. After protein fixation in 40% methanol and 5% phos-
phoric acid for 1 hour, the gels were stained with CBB G-250
for 12 hours. The gels were subsequently destained with
H2O, scanned using a Bio-Rad GS710 densitometer (Rich-
mond, CA), and converted into electronic files that were 
analyzed using the Image Master Platinum 5.0 image analy-
sis program (Amersham Biosciences).  
4. Matrix-assisted laser desorption/ionization time-of-flight 
Protein spots were excised from gels with a sterile scalpel
and placed into Eppendorf tubes. Proteins were digested
with trypsin (Promega, Madison, WI) as previously descri-
bed [11]. For matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry (MS) analy-
sis, peptides were concentrated using a POROS R2, Oligo R3
column (Applied Biosystems, Foster City, CA). After wash-
ing the column with 70% acetonitrile, 100% acetonitrile, and
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50 mM ammonium bicarbonate, samples were applied to the
R2, R3 column and eluted with cyano-4-hydroxycinamic acid
(Sigma, St. Louis, MO) in 70% acetonitrile and 2% formic acid
onto the MALDI plate (Opti-TOF 384-well Insert, Applied
Biosystems) [12]. MALDI-TOF MS analysis was performed
on a 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems)
equipped with a 355-nm Nd:YAG laser. The pressure in the
TOF analyzer was approximately 0.00010132 Pa. Mass spec-
tra were obtained in reflectron mode with an accelerating
voltage of 20 kV and sum of 500 laser pulses, and calibrated
using the 4700 calibration mixture (Applied Biosystems).
Data Explorer 4.4 (PerSeptive Biosystems, Framingham, MA)
was used for monoisotopic mass data acquisition and extrac-
tion. 
5. Mascot database search
The mascot algorithm (Matrix Science, Inc., Boston, MA)
was used to identify peptide sequences present in a protein
sequence database. The following database search criteria
were used: taxonomy, Homo sapiens (NCBInr database down-
loaded on Nov 1, 2012); fixed modification, carbamidome-
thylated (+57) at cysteine residues, variable modification,
and oxidized (+16) at methionine residues; maximum 
allowed missed cleavage, 1; and MS tolerance, 100 ppm.
Only peptides yielded by trypsin digestion were considered.
6. Serum levels of inter-alpha inhibitor 4 in patients with
HCC
Serum inter-alpha inhibitor 4 (ITIH4) levels were meas-
ured using an enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer's instructions (Cloud-Clone
Corp., Houston, TX). Serum samples were collected < 1 week
before and after the completion of LDTx.
7. Cell culture
The human HCC cell line Huh7 was maintained in Dul-
becco’s minimal essential medium (GIBCO, Carlsbad, CA)
supplemented with 10% (v/v) fetal bovine serum (GIBCO),
100 U/mL penicillin, and 100 µg/mL streptomycin (GIBCO)
at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
8. Expression constructs
For ITIH4 knockdown, pLKO-shITIH4 control and MIS-
SION shRNA clones were purchased from Sigma-Aldrich
(SHCLNG-NM_002218).
For ITIH4 overexpression, a pCNS-D2 human ITIH4 mam-
malian expression vector and control mock vector were pur-
chased from the Korea human gene bank (http://genbank.
kribb.re.kr/).
9. In vitro gene transfection
For lentivirus production and transduction, 60%-90% con-
fluent 293T cells in antibiotic-free medium were transfected
with pLKO-shITIH4 control or gene-specific shRNA clones
along with packaging plasmids. After 24 hours, medium con-
taining transfection reagent was replaced with fresh medium
containing antibiotics. At 48-hour post-transfection, cultured
medium harvest and transduction in Huh7 pLKO-shITIH4
control and MISSION shRNA clones lentiviral virion. Trans-
duced cells were selected in medium containing 10 µg/mL
of puromycin (GIBCO) for 6 days, and individual puro-
mycin-resistant clones were isolated. These clones were
propagated and screened for ITIH4 expression via reverse
transcriptionpolymerase chain reaction (RT-PCR). Stable
knockdown Huh7 clones were maintained in medium con-
taining 5 µg/mL of puromycin.
To generate ITIH4 overexpressing cells, Huh7 cells were
cultured to 70%-80% confluence in 60-mm dishes. Cells were
transfected with the empty or ITIH4 expression plasmid
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in 
accordance with the manufacturer’s recommendations.
Briefly, in each dish, plasmid DNA (4 µg) and 12 µL of Lipo-
fectamine were separately diluted in 100 µL Opti-MEM
media, mixed, and incubated at room temperature for 
20 minutes. The cells were refreshed with Opti-MEM media
after removal of the regular supplemented media. The mixed
DNA-Lipofectamine complexes were added to each dish
containing cells. The cells were incubated at 37°C for 8 hours
to facilitate transfection, after which growth media contain-
ing 10% serum was added. After transfection, cells were 
selected in medium containing 20 µg/mL of blasticidin
(GIBCO) for 6 days, and individual blasticidin-resistant
clones were isolated. These clones were propagated and
screened for ITIH4 expression via RT-PCR. Stable Huh7
overexpressing clones were maintained in medium contain-
ing 5 µg/mL of puromycin.
10. RT-PCR
Total RNA was extracted from Huh7 cells using TRIzol
reagent (Life Technologies, Carlsbad, CA). One microgram
of total RNA was reverse transcribed to cDNA using an 
Omniscript RT Kit (Qiagen, Valencia, CA) according to the
manufacturer's instructions. cDNA (1 µL) was subsequently
amplified via polymerase chain reaction (PCR) using a
TaKaRa PCR Thermal Cycler Dice Gradient (Takara Bio Inc.,
Shiga, Japan). The following PCR protocol was used: a 
4-minute denaturation step at 94°C and 29 cycles comprising
30 seconds of denaturation at 94°C, 15 seconds of annealing
648 CANCER  RESEARCH  AND  TREATMENT
Cancer Res Treat. 2018;50(3):646-657
at 57°C, and 30 seconds of elongation at 72°C. The following
primers were used: ITIH4, 5-GGAGCAAACTGTCTCCG-
CAT-3 and 5-AGAAAGTGG AACCTGAGTGGAC-3;
GAPDH, 5-GGCTGCTTTTAACTCTGGTA-3 and 5-ACT-
TGATTT TGGAGGGATCT-3.
11. Cell viability assay
Cell viability was evaluated using the using EZ-Cytox Cell
Viability Assay WST-1 Kit (Daeillab Service, Seoul, Korea) 
according to the manufacturer’s instructions. Briefly, 100 µL
of cell suspension (1104 cells per well) were added to each
well of a 96-well plate and cultured overnight. Next, 10 µL
of EZ-Cytox solution was added to each well, followed by a
2-hour incubation at 37°C. Absorbance was measured by
spectrophotometry (VersaMax ELISA Microplate Reader,
Molecular Devices, Eugene, OR) at 450 nm. Cell viability was
determined as a percentage by comparing the absorbance of
transfected and normal Huh7 cells.
12. In vitro migration assay
The invasiveness of stable shITIH4 knockdown or ITIH4
overexpressing cells was evaluated in 24-well chambers. The
invasion assay was performed using transwell cell culture
chambers (BD Biosciences, Bedford, MA) according to the
manufacturer's instructions. Briefly, a transwell with an 
8-µm-diameter pore membrane was coated with 20 µL of col-
lagen (500 µg/mL) and incubated overnight. Cells (2104) in
200 µL of serum-free medium were seeded into the upper
chamber of each transwell, and the lower chamber was filled
with 1 mL of RPMI-1640 containing 10% fetal bovine serum
to induce chemotaxis. After a 24-hour incubation period at
37°C in a humidified 5% CO2 atmosphere, the cells were
fixed in methanol and stained with hematoxylin and eosin,
and cells that had invaded through the pores to the lower
surfaces of the filters were counted under a microscope. Val-
ues were calculated by averaging the total numbers of cells
from three different, randomly selected fields. 
13. ITIH4 expression in tumors of patients with HCC who
received LDTx
Tumor tissues were obtained from patients with HCC who
underwent surgical resection at Severance Hospital. To 
investigate ITIH4 expression, specimens of liver tumors and
normal liver tissues were biopsied from liver cancer patients.
To generate frozen sections, tumor samples fixed in 4% for-
malin were snap-frozen over liquid nitrogen in Tissue-Tek
OCT compound (Sakura Finetek, Tokyo, Japan) and cryosec-
tioned (15 µm). Microwave antigen retrieval was performed
in citrate buffer (pH 6.0). Specimens were blocked in 3% 
hydrogen peroxide for 15 minutes to inactivate peroxidases,
followed by washing in phosphate-buffered saline and
blocking for 1 hour with 3% goat serum at room temperature.
Samples were incubated with a polyclonal mouse antibody
against ITIH4 (1:100, CL1858, Novus Biologicals, Littleton,
CO) and a biotinylated secondary antibody (Dako, Carpin-
teria, CA). For visualization, samples were incubated with
peroxidase-labeled streptavidin (Dako) and 3,3-diaminoben-
zidine (Dako, Glostrup, Denmark). Slides were subsequently
counterstained with hematoxylin.
14. Statistical analysis
The statistical significances of differences in the mean
ITIH4 according to patient and tumor characteristics were
determined using chi-square test and Mann-Whitney U test.
Survival rates were evaluated using the Kaplan-Meier
method, and correlations of between failure-free survival
and clinical factors as continuous variables were analyzed
using a Cox hazard proportional model. A Cox step-
wise regression model was used for a multivariate analysis.
Results
1. Study population and characteristics
Among the 51 treated patients, 10 representative patients
each with a good prognosis or poor prognosis were selected
according to clinical outcomes after LDTx (Fig. 1). The char-
acteristics of the two study groups are presented in Table 1.
The median ages of the good and poor prognosis groups
Fig. 1. Flow chart of patient selection. HCC, hepatocellular
carcinoma; LDTx, liver-directed therapy.
Patients with HCC treated with LDTx (n=51)
Patients selection
Good prognosis group
Patients with 
no treatment failure
during follow-up (n=10)
Poor prognosis group
Patients with 
early treatment failure
after LDTx (n=10)
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Table 1. Characteristics of patients
Characteristic Good prognosis (n=10) Poor prognosis (n=10) p-value
Age, median (range, yr) 63 (40-75) 51 (39-72) 0.492
Sex
Male 9 ( 8 ( > 0.99
Female 1 ( 2 (
Viral type
B 5 ( 10 ( 0.033
C 2 ( 0 (
NBNC 3 ( 0 (
Child-Pugh class
A 10 ( 9 ( > 0.99
B 0 ( 1 (
Previous treatment
No 7 ( 6 ( > 0.99
Yes 3 ( 4 (
Stage
II 3 ( 4 ( > 0.99
III 4 ( 4 (
IVA 3 ( 2 (
AFP, median (range, ng/mL) 2,639 (1.85 to > 10,043) 13,902 (5.08 to > 10,043) 0.314
PIVKA-II, median (range, mAU/mL) 336 (19 to > 2,000) 1,121 (37 to > 2,000) 0.661
NBNC, non-B non-C; AFP, -fetoprotein; PIVKA-II, protein induced by vitamin K absence-II.
Table 2. Treatment failure patterns of patients  
Patients (n=10) Local failure PFS Intrahepatic failure PFS Extra-hepatic failure PFS
Good prognosis
P1 No 26.4 No 26.4 No 26.4
P2 No 60.4 No 60.4 No 60.4
P3 No 60.9 No 60.9 No 60.9
P4 No 3.5 No 3.5 No 3.5
P5 No 12 No 12 No 12
P6 No 4.4 No 4.4 No 4.4
P7 No 7.3 No 7.3 No 7.3
P8 No 6.5 No 6.5 No 6.5
P9 No 5.8 No 5.8 No 5.8
P10 No 51 No 51 No 51
Poor prognosis
P1 No 2.7 Yes 1.1 Yes 0.1
P2 Yes 7.7 Yes 3.4 Yes 0
P3 No 8.6 No 8.6 Yes 0
P4 No 9 Yes 1 Yes 1
P5 No 24.5 Yes 0 Yes 15.4
P6 Yes 0.9 Yes 0.9 Yes 0.9
P7 Yes 6.1 Yes 0 Yes 4.9
P8 No 5.7 Yes 3.2 Yes 0
P9 No 7.4 Yes 3.1 Yes 0
P10 No 17.8 Yes 0 Yes 8.5
Local failure, failure in the tumor site; PFS, progression-free survival; P, patient.
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were 63 years (range, 40 to 75 years) and 51 years (range, 39
to 72 years), respectively. Most patients had International
Union Against Cancer stage II, III, and IVA HCC at the time
of diagnosis. Seven patients in the good prognosis group
(70%) and six patients in the poor prognosis group (60%)
were treatment-naïve before LDTx. Treatment-non-naïve 
patients underwent transarterial chemoembolization or
transarterial chemoinfusion before LDTx. The median serum
AFP levels of patients in the good and poor prognosis groups
were 2,639 ng/mL (range, 1.85 to 83,000 ng/mL) and 13,902
ng/mL (range, 5.08 to 83,000 ng/mL), respectively. The pre-
LDTx levels of protein induced by vitamin K antagonist-II in
the same groups were 336 mAU/mL (range, 19 to 2,000
mAU/mL) and 1,121 mAU/mL (range, 37 to 2,000 mAU/
mL), respectively. The corresponding median total pre-
scribed RT doses were 50 Gy (range, 45 to 54 Gy) and 49.3
Gy (range, 45 to 54 Gy), respectively. The treatment failure
patterns of each study group are described in Table 2. No
treatment failures were reported in the good prognosis
group during follow-up. In the poor prognosis group, 
although local failures occurred in three patients, most treat-
ment failures were regional failures (9/10) or distant metas-
tasis (10/10), and poor prognosis group showed worse
overall survival at 1 year and 2 years than good prognosis
group (20% vs. 40%, 10% vs. 40%).
2. 2-DE assessment of differentially expressed proteins in
sera of patients with HCC according to prognosis 
To identify a useful post-LDTx prognostic serum bio-
marker, pre- and post-LDTx serum samples were collected
from each patient and pooled in both study groups. The six
most abundant serum proteins were removed using a MARS
column as described above to facilitate the detection of low-
Fig. 2. Differentially expressed proteins identified in pre- and post-LDTx samples according to treatment outcomes in patients
with hepatocellular carcinoma. Protein spots were identified using two-dimensional electrophoresis. Green and red circles
indicate paired and non-paired spots, respectively. LDTx, liver-directed therapy; SDS-PAGE, sodium dodecyl sulfate poly-
acrylamide gel electrophoresis.
Pre-LDTx
Good treatment
outcome
Poor treatment
outcome
Post-LDTx
SD
S-
PA
GE
pH 3.0 pH 10 pH 3.0 pH 10
SD
S-
PA
GE
pH 3.0 pH 10 pH 3.0 pH 10
VOLUME 50 NUMBER 3 JULY 2018  651
Eun-Jung Lee, ITIH4 as a Potential Prognostic Factor in HCC
abundance proteins. Following 2-DE, 481 and 317 spots were
detected in pre- and post-LDTx samples, respectively, from
the good prognosis group, of which 41 exhibited significant
(more than 2-fold) differences in expression between pre-
and post-LDTx levels. In the poor prognosis group, 362 and
357 spots were detected in pre- and post-LDTx samples, 
respectively, and 33 spots were found to be significantly dif-
ferentially expressed (more than 2-fold) between pre- and
post-LDTx samples (Fig. 2). 
3. MALDI-TOF analysis of differentially expressed protein
spots
All 74 differentially expressed proteins identified by com-
paring the pre- and post-LDTx samples of the good and poor
prognosis groups were selected via imaging analysis. Subse-
quently, 30 proteins were identified by MALDI-TOF/TOF
MS from among these differentially expressed protein spots,
and a NCBI Reference Sequence human protein databases
search was conducted (Table 3). As shown in Table 3, 4 of
these proteins—ITIH4, inter-alpha-trypsin inhibitor heavy
Table 3. Serum biomarkers identified via comparison of pre- and post-LDTx in patients with HCC who had a good or poor
prognosis 
Patient group Protein No. Protein name Fold change Category p-value
Good prognosis 258 Inter-alpha (globulin) inhibitor H4 6.1 Cancer < 0.05
(plasma kallikrein-sensitive glycoprotein) 
278 Inter-alpha-trypsin inhibitor heavy chain H4 5.7 Cancer
isoform 2 precursor
400 Gi|119581148 (keratin 9)+gi|186772 (keratin 1) 4.6 Cancer < 0.05
427 Fibrinogen gamma chain, isoform CRA_j 5.4 Cancer
Poor prognosis 2,353 Chain B, X ray structure of the complex between 4.7 Metabolism < 0.05
carbonic anhydrase I and the phosphonate 
antiviral (CA1)
2,412 Unnamed protein product 5.5 Cancer
2,477 Chain D, crystalline human carbonmonoxy 19.9 Metabolism < 0.05
hemoglobin S
LDTx, liver-directed therapy; HCC, hepatocellular carcinoma.
Patient
Good prognosis (ITIH4)
Aa) (ng/mL) Bb) (ng/mL) B-A (ng/mL) Fold change
P1 47.9 253.3 205.4 5.3
P2 84.6 82.5 2.1 1
P3 12.8 244 231.1 19
P4 34 201.1 167.1 5.9
P5 51.9 182.1 130.2 3.5
P6 53.1 214.6 161.5 4
P7 56.4 206.4 150 3.7
P8 13.4 176.1 162.7 13.1
P9 35.2 40.3 5.2 1.1
P10 36.8 217.4 180.6 5.9
Average 42.6 181.8 139.2 6.3
Table 4. ELISA confirmation using serum samples from each patient in the good prognosis group
ELISA, enzyme-linked immunosorbent assay; ITIH4, inter-alpha inhibitor 4; P, patient. a)Pre-radiotherapy, b)Post-radiother-
apy.
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chain H4 isoform 2 precursor, keratin 9/1 complex, and fib-
rinogen gamma chain—were expressed in post-LDTx sam-
ples at levels 4-fold higher or more than those in pre-LDTx
samples from the good prognosis group. In contrast, 3 pro-
teins—carbonic anhydrase I (CA1), unnamed protein, and
human carbonmonoxyhemoglobin S—were downregulated
by more than 4-fold in post-LDTx samples from the poor
prognosis group, compared to pre-LDTx samples. In partic-
Fig. 3. Inter-alpha inhibitor 4 (ITIH4) inhibited the migration of Huh7 cells. (A) ITIH4 mRNA expression in Huh7 cells.
ITIH4 was downregulated in Huh7 cells infected with ITIH4 shRNA lentiviral vectors. For ITIH4 overexpression, Huh7 cells
were transfected with the ITIH4 pCNS-D2 vector. (B) Cell viability of ITIH4 knockdown or overexpressing Huh7 cells. (C)
Migration ability increased in response to ITIH4 downregulation in Huh7 cells (200). (Continued to the next page)
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Fig. 3. (Continued from the previous page) (D) Migration ability decreased in ITIH4 overexpressing Huh7 cells (200). Data are
representative of the means and standard deviations of three independent experiments. n.s., not significant. **p < 0.01, 
***p < 0.001 compared to control.
D
M
ig
ra
te
d 
ce
ll n
um
be
r
60
80
40
20
0
Mock ITIH4 O/E
Mock ITIH4 O/E
Fig. 4. Immunohistochemical analysis of inter-alpha inhibitor H4 (ITIH4) in surgical specimens of human hepatocellular
carcinoma. (A) ITIH4 expression was significantly higher in cancer tissues than in non-tumor liver tissues (200). (B) Higher
levels of ITIH4 were detected in the tumors of patients with a good prognosis (representative: patient 1), compared with 
tumors of patients with a poor prognosis (representative: patient 2) (200).
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ular, the pre-LDTx level of ITIH4 in the good prognosis
group was more than 5-fold higher than that in the poor
prognosis group (data not shown). These results suggest that
ITIH4 may be an important biomarker that could predict bet-
ter treatment outcomes of patients receiving LDTx for HCC.
4. Up-regulation of serum ITIH4 in post-LDTx level com-
pare to pre-LDTx of patients with good prognosis 
To confirm the 2-DE results and further validate ITIH4 as
a possible prognostic biomarker of HCC, serum samples
from all patients with a good prognosis were subjected to
ELISA. The mean serum ITIH4 concentration was signifi-
cantly higher in post-LDTx samples when compared with
pre-LDTx samples (181.8±20.39 pg/mL vs. 42.6±5.78 pg/mL)
(Table 4). Most patients in the good prognosis group exhib-
ited a post-LDTx increase in ITIH4 levels relative to the pre-
LDTx levels, consistent with the 2-DE analysis results.
It may cause a question on whether ITIH4 could be simply
hepatitis B virus (HBV)associated protein. However, in a
separate experiment on patients with diverse viral back-
ground (B, C, and non-B non-C) all patients showed 
increased postTx ITIH4 comparing to preTx regardless of
viral type, suggesting ITIH4 could be an independent moiety
from B-virus (S1 Fig.). 
5. ITIH4 as a suppressor of migration and metastasis in
HCC
To investigate the role of ITIH4 in HCC, we generated
ITIH4 knockdown Huh7 cells (shITIH4) or ITIH4 overex-
pressing Huh7 cells (ITIH4 O/E) (Fig. 3A) and subjected
these cells to a transwell invasion assay. ITIH4 knockdown
or overexpression did not affect cell viability (Fig. 3B). As
shown in Fig. 3C, the invasiveness of Huh7 cells was 
increased by ITIH4 knockdown. In consistent with this 
result, ITIH4 overexpression reduced the invasiveness of
Huh7 cells relative to controls (Fig. 3D). These results indi-
cate that ITIH4 can suppress the invasion and migration of
HCC.
6. ITIH4 expression in patients’ tumor tissue
Finally, we examined ITIH4 expression in tumor tissues
from patients with HCC. As shown in Fig. 4A, ITIH4 expres-
sion in tumor tissues was significantly higher than that in
normal liver tissues from the same patient. As demonstrated
by the examples in Fig. 4B, higher ITIH4 expression was 
observed in a patient with a good prognosis (patient 1), com-
pared to the patient with a poor prognosis (patient 2). These
results supported other results in this study on the role of
ITIH4 as a prognostic marker for HCC.  
Discussion
In the present study, we performed a 2-DE analysis to
search for potential serum-based biomarkers that could pre-
dict the treatment outcomes of patients with HCC after
LDTx. We identified four proteins—ITIH4, inter-alpha-
trypsin inhibitor heavy chain H4 isoform 2 precursor, keratin
9/1 complex, and fibrinogen gamma chain—for which the
post-LDTx expression levels were more than 4-fold higher
than the pre-LDTx levels in the good prognosis group. In the
poor prognosis group, we identified three proteins—CA1,
unnamed protein, and human carbonmonoxy hemoglobin
S—for which the post-LDTx levels decreased by more than
4-fold relative to the pre-LDTx levels. Moreover, pre-LDTx
levels of ITIH4 were more than 5-fold higher in patients with
a good prognosis, compared to those with a poor prognosis.
We selected three proteins—ITIH4, keratin 9/1, and CA1—
that are related to cancer progression as well as present high
variation among the identified total proteins for validation
as useful biomarkers. Serum levels of the selected-target pro-
teins were evaluated in each patient via ELISA. As results,
ITHI4 exhibited the most consistency as a potential prognos-
tic factor for HCC treatment than other candidate proteins
when all results were combined. The keratin 9/1 ELISA 
results were not consistent with the 2-DE analysis results. In
patients with a poor prognosis, post-LDTx serum CA1 levels
decreased by an average of two fold relative to pre-LDTx lev-
els (data not shown). Furthermore, patients with HCC and a
good prognosis exhibited higher levels of ITIH4 in tumors,
compared the levels in tumors from patients with a poor
prognosis.
ITIH4 is a member of a liver-restricted serine protease 
inhibitor. This protein belongs to the ITIH family, the mem-
bers of which are found at relatively high concentrations in
human plasma [13]. ITIH family members have been 
reported to contribute to extracellular matrix stability and
have been shown to be involved in processes such as tumor
cell migration and metastasis [14]. Hamm et al. [15] reported
that multiple human solid cancers frequently exhibited
ITIH4 downregulation, which might be associated with the
initiation and progression of these malignancies.
Indeed, we found that ITIH4 overexpression could inhibit
the invasiveness of Huh7 cells, whereas knockdown of ITIH4
increased the migration of these cells. These results indicate
that ITIH4 plays an important role in the invasiveness and
migration of HCC. 
Recently, ITIH4 was identified as a valuable diagnostic 
indicator in patients with HBV-associated HCC. The expres-
sion of this protein is significantly lower in patients with
HBV-associated HCC than in those with liver cirrhosis and
hepatitis [16]. ITIH4 is mainly expressed in the liver and is
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secreted into the blood [17]. In this study, ITIH4 was 
expressed at higher levels in tumors than in normal liver tis-
sues, suggesting that serum ITIH4 levels are mainly tumor-
derived. ITIH4 was also expressed at significantly higher
levels in the tumors of patients with HCC who had a good
prognosis, compared to those with a poor prognosis. In 
addition, most patients with a poor prognosis having low
levels of ITIH4 exhibited worse outcomes in terms of either
intrahepatic or extrahepatic failure-free survival in this
study. This finding suggests that ITIH4 identified via serum
protein profiling could serve as a potential prognostic factor
in LDTx-treated patients with HCC.
However, this study has some limitations, including the
small number of patients who were treated with LDTx and
the lack of validation in patients with HCC at different dis-
ease stages. Also, it is unclear whether ITIH4 is the marker
predicting prognosis just in patients who receive radiation
therapy or whether the marker can generally predict the
prognosis in HCC patients. Since ITIH4 was identified as the
marker predicting prognosis through comparative analysis
between pre-RT and post-RT in patients with liver cancer,
ITIH4 seems to be a biomarker to predict prognosis in 
patients receiving RT. Nevertheless, as mentioned above,
ITIH4 was a diagnostic and prognostic indicator in HBV-
associated HCC. Accordingly, ITIH4 might be a biomarker
in HCC patients who don’t receive RT as well as HCC 
patients who receive RT. In our study, preTx level of ITIH4
was higher in the good prognosis group compared to poor
prognosis, suggesting that ITIH4 per se would be a bio-
marker regardless of the treatment. Therefore, additional
large-scale studies are needed to confirm regarding this issue
in various HCC stages. 
In conclusion, we identified ITIH4 as a novel biomarker
that could predict clinical outcomes in patients with locally
advanced HCC who were receiving LDTx. Given its involve-
ment in tumor progression and invasion, as well as metasta-
sis, serum ITIH4 appears to be an important mediator related
to the clinical outcomes of locally advanced HCC.
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